UNSPSC 51202005: Resiquimod

This classification denotes a biological response modifier with the molecular formula C17H22N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V3DMU7PVXF, chemically known as 1h-imidazo(4,5-c)quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl- but generally known as resiquimod, which bears US NIH Compound Identifier 159603. The term RESIQUIMOD is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44).

Most nations schedule resiquimod under HS 29339990 and SITC 51577. As of Q4 2014, RESIQUIMOD remains the US FDA Preferred Term for this commodity. Resiquimod bears US NLM identifiers UMLS ID C0389573 and NCI Concept Code C63958. SMILES: CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N.

UNSPSC 51202005 Resiquimod is a Commodity code for a specific immunological agent, but the recent state and local activity tagged to it reflects procurement of yellow fever vaccine rather than resiquimod itself—a mismatch that signals the code sees little direct relevant activity in state and local markets right now. The Mississippi State Department of Health posted a sole source procurement notice on July 13, 2026 for Yellow Fever Vaccine from Sanofi Pasteur, Inc., with an objection deadline of August 3, 2026. This represents a notice of proposed sole source purchase rather than a competitive solicitation; the department must receive and substantiate objections demonstrating alternative vendor availability before proceeding, and if the sole source designation is challenged, the Public Procurement Review Board will require the department to prove exclusive availability. The notice does not specify quantity, contract term, estimated value, or pricing.

The code shows no broader geographic spread or pattern of repeat issuing bodies in recent state and local procurement records. The single documented opportunity originates from a state health department and reflects a specialized medical-commodity acquisition rather than a sustained market for resiquimod. Firms pursuing this code should monitor state and local health department procurement channels for immunological-agent solicitations, but current activity does not support a near-term pipeline under the code's nominal scope.